Open AccessChronic heart failure – modification of treatment paradigm
Author(s) -
Svetla. Nasonova,
И. В. Жиров,
S. N. Tereshchenko
Publication year - 2022
Publication title -
consilium medicum
Language(s) - English
Resource type - Journals
eISSN - 2542-2170
pISSN - 2075-1753
DOI - 10.26442/20751753.2022.1.201445
Subject(s) - heart failure , dapagliflozin , ejection fraction , medicine , cardiology , intensive care medicine , medical prescription , diabetes mellitus , pharmacology , type 2 diabetes , endocrinology
The relevance of chronic heart failure (CHF) remains high. Despite significant advances in basic therapy for CHF patients, the prognosis remains poor. The prescription of inhibitors of sodium-glucose cotransporter type 2 dapagliflozin made it possible to change the paradigm of treatment of patients with CHF with low left ventricular ejection fraction.